Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Sep 29:4:256.
doi: 10.3389/fonc.2014.00256. eCollection 2014.

Treatment algorithms for patients with metastatic non-small cell, non-squamous lung cancer

Barbara Melosky  1
Affiliations
Review

Treatment algorithms for patients with metastatic non-small cell, non-squamous lung cancer

Barbara Melosky. Front Oncol. .

Abstract

A number of developments have altered the treatment paradigm for metastatic non-small cell, non-squamous lung cancer. These include increasing knowledge of molecular signal pathways, as well as the outcomes of several large-scale trials. As a result, treatments are becoming more efficacious and more personalized, and are changing the management and prognosis of non-small cell lung cancer patients. This is resulting in increased survival in select patient groups. In this paper, a simplified algorithm for treating patients with metastatic non-small cell, non-squamous lung cancer is presented.

Keywords: chemotherapy; metatstatic non-squamous NSCLC; systemic therapy; targeted therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A simplified treatment algorithm for patients with metastatic non-small cell non-squamous lung cancer. Patients are divided into three groups based on histology and EGFR and ALK mutation status. Selection of therapies is based on these groups. The dashed boxes indicate that maintenance is optional in group C patients.
Figure 2
Figure 2
Oncogenic drivers in lung adenocarcinoma (–29).
See this image and copyright information in PMC

References

    1. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med (2002) 346(2):92–810.1056/NEJMoa011954 - DOI - PubMed
    1. Gazdar AF, Linnoila RI. The pathology of lung cancer – changing concepts and newer diagnostic techniques. Semin Oncol (1988) 15(3):215–25 - PubMed
    1. Dubinski W, Leighl NB, Tsao M-S, Hwang DM. Ancillary testing in lung cancer diagnosis. Pulm Med (2012) 2012:1–810.1155/2012/249082 - DOI - PMC - PubMed
    1. Ellis PM, Blais N, Soulieres D, Ionescu DN, Kashyap M, Liu G, et al. A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. J Thorac Oncol (2011) 6(8):1379–9110.1097/JTO.0b013e318220cb8e - DOI - PubMed
    1. Vincent MD, Kuruvilla MS, Leighl NB, Kamel-Reid S. Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRAS. Curr Oncol (2012) 19(Suppl):1.10.3747/co.19.1149 - DOI - PMC - PubMed